Dupixent May Be Strong Growth Driver for Sanofi in the Future



Dupixent growth trends

Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS). The companies managed to reach 5,100 of the 7,000 targeted physicians for creating awareness for Dupixent by the end of 2Q17. Of the 300,000 eligible atopic dermatitis (or AD) patients in the United States, Dupixent was already being prescribed to 13,000 patients within a few months of its market launch. To know more about regulatory approvals and label expansion plans for Dupixent, please refer to Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis.

Sanofi makes up 1.5% of the PowerShares International Dividend Achievers ETF’s (PID) total portfolio holdings.

Article continues below advertisement

Payer access

Payers such as Express Scripts and CVS Caremark have already included Dupixent in their formularies and have placed preauthorization constraints consistent with Dupixent’s label. At the end of 2Q17, about 30.0% of the covered lives in the United States had access to Dupixent. Sanofi and Regeneron plan to further expand market access for this drug by the end of 2017. Dupixent is expected to enable Sanofi to compete more effectively with dermatology players such as Mylan (MYL) and Perrigo.

At the end of 2Q17, the prior authorization approval rate for Dupixent across all health plans was 73.0%. Sanofi has also contracted with certain payers for extending access to Dupixent. For these health plans, the prior authorization rate for the drug has been as high as 83.0%. Sanofi reported 26.0 million euros in Dupixent sales in 2Q17, mainly due to a solid end-user demand and low inventory.

On September 28, 2017, Dupixent secured marketing authorization from the European Commission as a treatment option for patients with moderate to severe AD who are eligible for systemic therapy. Sanofi and Regeneron are also waiting for top-line results from a Phase 3 trial evaluating Dupixent for the asthma indication. Based on this study, the companies aim to file a supplemental biologics indication to expand Dupixent’s label in 4Q17.

In the next part of this series, we’ll look at the performance of Kevzara.


More From Market Realist